📋 PRECISION BIOSCIENCES, INC. (DTIL) - Financial Results
Filing Date: 2026-03-12
Accepted: 2026-03-12 07:30:09
Event Type: Financial Results
Event Details:
PRECISION BIOSCIENCES, INC. (DTIL) Reports the reporting period Financial Results
PRECISION BIOSCIENCES, INC. (DTIL) announced its financial results for the period ending the reporting period.
Key Financial Highlights:
Revenue: 34264
Net Income: 20133
EPS: Not disclosed
Cash and equivalents: 137153
targeting of the root cause of the disease; expectations concerning the receipt of initial clinical data from multiple patients for PBGENE-DMD by year-end 2026
targeting the elimination of cccDNA leading to sustained loss of HBV DNA. The FDA has previously provided guidance that sustained loss of HBV DNA is an approvable endpoint for chronic hepatitis B.Further details on the trial can be found on Precision’s website and on clinicaltrials.gov identifier NCT0668
📋 PRECISION BIOSCIENCES, INC. (DTIL) - Financial Results
Filing Date: 2026-03-12
Accepted: 2026-03-12 07:30:09
Event Type: Financial Results
Event Details:
📊 Key Financial Metrics (Year-over-Year Comparison):
💼 Business Developments:
Structured Data: